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Caspofungin: a new therapeutic option for
fungal endocarditis
A recent report in Clinical Microbiology and Infec-
tion described the successful treatment with
caspofungin of a patient with oropharyngeal
candidiasis caused by strains of Candida albicans
and Candida glabrata resistant to azoles [1]. To
build on this experience, we wish to describe a
patient with a severe fungal infection (infective
endocarditis) who also recovered following treat-
ment with this new drug.
The patient was a male, aged 22 years, who
presented with a history of moderate chest pain,
progressive dyspnoea and high fever lasting for
2 weeks. He had a diastolic murmur (IV ⁄VI) on
aortic focus and a prominent cardiomegaly on the
chest radiograph. The echocardiograph showed
signiﬁcant pericardial effusion, a bicuspid aortic
valve with large vegetations, and severe valvular
regurgitation. All four blood cultures yielded
non-albicans Candida spp., identiﬁed subsequently
as Candida guilliermondii by standard methods.
Antifungal therapy with intravenous caspofungin
(50 mg every 24 h) was initiated and, after 72 h
(still with positive blood cultures), a sub-valvular
abscess was removed surgically and a mechanical
prosthesis was implanted. C. guilliermondii was
also isolated from the valve, and susceptibility
testing [2] indicated that the isolate was sensitive
to ﬂuconazole (MIC 2 mg ⁄L), amphotericin B
(MIC 0.5 mg ⁄L) and caspofungin (MIC 1 mg ⁄L).
The patient recovered without fever and with no
effects of secondary treatment but, after 21 days,
an aortic anterior perianulum aneurism (36 ·
18 mm), with prosthetic dehiscence, was detected
by transoesophageal echocardiography. At this
time, the patient was afebrile, in a stable condi-
tion, with repeated negative blood cultures. On
day 42, the aortic root was reconstructed surgi-
cally. Valvular tissue cultures yielded no growth,
and the patient was switched to oral ﬂuconazole
(400 mg four-times-daily) and maintained on this
regimen for 1 month. After a further 20 months,
the patient was asymptomatic, blood cultures
were negative, and echocardiography ﬁndings
were normal.
Infective endocarditis caused by Candida spp. is
being reported with increasing frequency. Intra-
venous drug abuse, cardiovascular surgery and
long-term intravenous catheters are all factors
predisposing to this life-threatening condition.
Medical treatment is difﬁcult, and often inade-
quate, thereby necessitating a surgical approach
[3]. C. guillermondii is usually associated with
cutaneous infections, and invasive disease is very
infrequent [4]. Amphotericin B is recommended
as the drug of choice for the treatment of non-
albicans Candida spp. in this setting [5]. However,
the secondary effects (i.e., nephrotoxicity) of
amphotericin B may limit the potential beneﬁts
in patients with poor haemodynamic status.
These considerations led us to choose caspofun-
gin as the best therapeutic option, as its efﬁcacy in
invasive candidaemia has been demonstrated in
recent reports, albeit excluding cases involving
endocarditis [6]. The favourable evolution and the
negative tissue cultures following the second
surgical intervention in this case provide evidence
of a microbiological cure. To our knowledge, this
is the ﬁrst reported case of fungal endocarditis
treated and cured with caspofungin, which seems
to offer a reasonable alternative for the medical
treatment of this serious infection.
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